Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acucela Strikes Third Ophthalmology Deal With Otsuka For Glaucoma Drug

This article was originally published in The Pink Sheet Daily

Executive Summary

Building on deals in AMD and dry eye, the U.S. eye care startup will conduct trials on a novel glaucoma treatment, with an option to co-promote.
Advertisement

Related Content

Otsuka Plans ¥1 Trillion IPO To Expand Beyond Abilify And Soyjoy
Glaucoma's Changing Of The Guard
Otsuka Looks To IPO To Fund Overseas Expansion
Sirion Therapeutics Inc.
Merck Signs Licensing Deal With Santen, Marking Second Deal For Japan’s Top Ophthalmology Maker
Acucela, Otsuka Enter Deals For Eye Drugs

Topics

Advertisement
UsernamePublicRestriction

Register

PS071234

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel